Alzamend Neuro, Inc.
ALZN
$2.15
-$0.05-2.27%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.27% | 15.57% | 54.61% | 65.92% | 61.07% |
| Total Depreciation and Amortization | 59.06% | 29.53% | 0.00% | 17.05% | 41.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -46.20% | -57.67% | -65.02% | -75.45% | -83.61% |
| Change in Net Operating Assets | 94.58% | -410.81% | -463.61% | -281.02% | -169.73% |
| Cash from Operations | 28.65% | -30.65% | 20.58% | 19.52% | 10.61% |
| Capital Expenditure | -133.33% | -133.33% | -103.80% | 38.86% | 38.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -133.33% | -133.33% | -103.80% | 38.86% | 38.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -36.46% | 115.94% | 115.94% | 117.01% | 13,061.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -49.04% | 141.35% | 268.39% | 599.01% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -47.78% | 122.79% | 185.85% | 390.97% | 64,912.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -90.85% | 982.91% | 174.98% | 143.36% | 143.34% |